This is the authors' abstract. We don't add key points for this paper.
As new migraine therapies emerge, it is crucial for measures to capture the complexities of health-related quality of life (HRQoL) improvement beyond improvements in monthly migraine day (MMD) reduction. Investigations into the correlations between MMD reduction, symptom management, and HRQoL are lacking, particularly those that focus on improvements in canonical symptoms and improvement in patient-identified most-bothersome symptoms (PI-MBS), in patients treated with eptinezumab. This exploratory analysis identified efficacy measures mediating the effect of eptinezumab on HRQoL improvements in patients with migraine.
Answers are grounded in this paper and cite their sources.
No takes yet. Share an insight, caveat, or question.
Jönsson et al. (2024) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: